Comparison of the actions of kallidin and bradykinin in the skin of normal and psoriatic subjects.
With the recent development of selective drugs acting on the kinin system and the identification of a kallikrein-like enzyme from psoriatic blister fluid, there is now much interest in the possible role of kinins in psoriasis. We have examined the time-course of the inflammatory (weal and flare) responses to intradermal kallidin (lysbradykinin) and bradykinin in normal volunteers, and have compared the dose-response effect of these agents in normal volunteers and patients with psoriasis. Initially, normal subjects (n = 5) received coded intradermal injections of 50 microliters normal saline containing kallidin or bradykinin (0.1, 0.5, 1.0 and 5.0 micrograms). Weal volume, weal area and flare area were calculated at 5, 15, 30 and 60 min by measuring two perpendicular diameters and change in skinfold thickness. Weal and flare measurements were subsequently made at 15 and 5 min, respectively. Patients with psoriasis (n = 9) and normal subjects (n = 10) were given intradermal injections of kallidin (0.1 and 1.0 microgram) and bradykinin (0.1, 0.5 and 1.0 microgram) in clinically normal forearm skin, using histamine and normal saline as controls. The dose-response effects of kallidin on weal and flare responses in human skin were established in the study and compared with those of bradykinin. There was wide inter-individual variability for both agents and, although mean responses to the highest doses of kallidin and bradykinin were decreased in psoriatic skin, no significant differences were found between the psoriatic and normal group for kallidin, bradykinin or histamine. Hence, there do not appear to be any obvious altered vascular responses to kallidin or bradykinin in patients with psoriasis, despite the fact that kinins may be generated in psoriatic tissue.
Marshman
G
G
University of Bristol, Department of Dermatology, Bristol Royal Infirmary, UK.
Burton
J L
JL
Archer
C B
CB
D000328:Adult; D001920:Bradykinin / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D007609:Kallidin / Q000494:pharmacology*; D008297:Male; D011565:Psoriasis; D014581:Urticaria / Q000139:chemically induced*; D014665:Vasodilator Agents / Q000494:pharmacology*
D014665:Vasodilator Agents; D007609:Kallidin; D001920:Bradykinin